Wildfires and wildlife – DVM 360
February 7th, 2025 2:51 amWildfires and wildlife DVM 360
Go here to read the rest:
Wildfires and wildlife - DVM 360
Legislation filed to pave the way for MSU School of Veterinary Medicine – WHOP
February 7th, 2025 2:51 amLegislation filed to pave the way for MSU School of Veterinary Medicine WHOP
More here:
Legislation filed to pave the way for MSU School of Veterinary Medicine - WHOP
Exploring the rise in tick populations – DVM 360
February 7th, 2025 2:51 am Read More...This chief medical officer got her start as a veterinarian, the ‘hottest’ job for 2025Heres her advice for getting into the hugely growing industry -…
February 7th, 2025 2:51 amSee the rest here:
This chief medical officer got her start as a veterinarian, the 'hottest' job for 2025Heres her advice for getting into the hugely growing industry -...
DR. DENA LODATO SELECTED AS TOP VETERINARY SURGEON OF THE DECADE BY IAOTP – EIN News
February 7th, 2025 2:51 amDR. DENA LODATO SELECTED AS TOP VETERINARY SURGEON OF THE DECADE BY IAOTP EIN News
See the article here:
DR. DENA LODATO SELECTED AS TOP VETERINARY SURGEON OF THE DECADE BY IAOTP - EIN News
Long Island University honors the Lewyts, renames veterinary school – Long Island Press
February 7th, 2025 2:51 amLong Island University honors the Lewyts, renames veterinary school Long Island Press
View original post here:
Long Island University honors the Lewyts, renames veterinary school - Long Island Press
Reptiland cited for birds being crushed and killed – NorthcentralPA.com
February 7th, 2025 2:51 amReptiland cited for birds being crushed and killed NorthcentralPA.com
See the original post here:
Reptiland cited for birds being crushed and killed - NorthcentralPA.com
Rakovina Therapeutics Announces Additional Synthesized Compounds in its AI-Driven Cancer Drug Discovery Program
February 7th, 2025 2:51 amVANCOUVER, British Columbia, Feb. 06, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO), a biopharmaceutical company advancing cancer therapies based on DNA-damage response technologies, announces continued advancement of its AI-driven drug discovery program. Over the next four months, additional small-molecule drug candidates, designed in collaboration with Pharma Inventor Inc., will be synthesized and delivered for further evaluation.
Continue reading here:
Rakovina Therapeutics Announces Additional Synthesized Compounds in its AI-Driven Cancer Drug Discovery Program
Wave Life Sciences Announces Initiation of Phase 1 INLIGHT Clinical Trial of WVE-007 in Obesity
February 7th, 2025 2:51 amWVE-007 is a novel, long-acting GalNAc-siRNA targeting INHBE mRNA – a genetically validated target that provides a new approach for healthy, sustainable weight loss (fat loss with muscle preservation)
See the original post here:
Wave Life Sciences Announces Initiation of Phase 1 INLIGHT Clinical Trial of WVE-007 in Obesity
Intelligent Bio Solutions expects to achieve 32.6% Gross Profit Expansion and Increased Profitability on Higher-Margin Sales
February 7th, 2025 2:51 amGross profit expected to surge by 32.6%
Read the original:
Intelligent Bio Solutions expects to achieve 32.6% Gross Profit Expansion and Increased Profitability on Higher-Margin Sales
BioAdaptives Welcomes UFC Senior Executive Reed Harris to Its Board of Advisors
February 7th, 2025 2:50 amHarris, the Senior Vice President of Athlete Development and Marketing at the Ultimate Fighting Championship, has a distinguished career spanning over 40 years Harris, the Senior Vice President of Athlete Development and Marketing at the Ultimate Fighting Championship, has a distinguished career spanning over 40 years
Visit link:
BioAdaptives Welcomes UFC Senior Executive Reed Harris to Its Board of Advisors
North Texas Took Center Stage at Advanced Therapies Week 2025, Highlighting Innovation and Collaboration in Life Sciences
February 7th, 2025 2:50 amDALLAS, Feb. 06, 2025 (GLOBE NEWSWIRE) -- From January 20-23, 2025, North Texas took center stage as a global hub for innovation during Advanced Therapies Week (ATW) 2025. This signature event showcased the intersection of cutting-edge science, transformative healthcare solutions, and dynamic regional collaboration. Hosted in Dallas, ATW 2025 convened industry leaders, researchers, and visionaries to explore the future of cell and gene therapy. From breakthroughs in gene editing to scalable advancements in cell therapy manufacturing, the event underscored the immense potential of advanced therapies to transform medicine and improve lives worldwide.
Read the original:
North Texas Took Center Stage at Advanced Therapies Week 2025, Highlighting Innovation and Collaboration in Life Sciences
Denali Therapeutics Announces Primary Analysis and Long-Term Follow-Up of Phase 1/2 Study in Hunter Syndrome (MPS II) with Tividenofusp Alfa
February 7th, 2025 2:50 amSOUTH SAN FRANCISCO, Calif., Feb. 06, 2025 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI), today announced the primary analysis of the Phase 1/2 study in 47 participants with Hunter syndrome (MPS II) in the 24-week treatment period and additional long-term follow-up of its investigational therapeutic tividenofusp alfa (DNL310). These data, along with recent Breakthrough Therapy designation, further support the company’s plan to submit a biologics license application (BLA) in early 2025 for accelerated approval and deliver this potential treatment to the Hunter syndrome community in late 2025 or early 2026. The Phase 1/2 results are being presented this week at the 21st Annual WORLDSymposium™ conference in San Diego, California.
GUERBET : 2024 revenue.
February 7th, 2025 2:50 am2024 revenue
Go here to see the original:
GUERBET : 2024 revenue.
Shareholding declaration Valneva SE – January 2025
February 7th, 2025 2:50 amVALNEVA
Here is the original post:
Shareholding declaration Valneva SE - January 2025
Ipsen – January 2025 – Monthly information relative to the total number of voting rights and shares composing the share capital
February 7th, 2025 2:50 amMonthly information relative to the total number of voting rights and shares composing the share capital
See the original post:
Ipsen - January 2025 - Monthly information relative to the total number of voting rights and shares composing the share capital
CARBIOS is pleased that the European Commission has authorised the ‘Circular Economy’ State aid scheme
February 7th, 2025 2:50 amClermont-Ferrand (France), 6 February 2025 (18:30 CET). CARBIOS, (Euronext Growth Paris : ALCRB), a pioneer in the development and industrialization of biological technologies to reinvent the life cycle of plastic and textiles, is pleased that the European Commission has authorised the ‘Circular Economy’ State aid scheme.
60 Degrees Pharma Announces Closing of $1.075 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
February 7th, 2025 2:50 amRaised approximately $2.118 million in gross proceeds since the beginning of 2025 Raised approximately $2.118 million in gross proceeds since the beginning of 2025
Original post:
60 Degrees Pharma Announces Closing of $1.075 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Senseonics Completes CE Mark Submission for Eversense 365, World’s Longest-lasting Continuous Glucose Monitor
February 7th, 2025 2:50 amGERMANTOWN, Md., Feb. 06, 2025 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NYSE American: SENS) a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced it has filed for CE Mark registration for the Eversense® 365 CGM system.
Continue reading here:
Senseonics Completes CE Mark Submission for Eversense 365, World’s Longest-lasting Continuous Glucose Monitor
Fulcrum Therapeutics to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference
February 7th, 2025 2:50 amCAMBRIDGE, Mass., Feb. 06, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (the “Company”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced that management will participate in a fireside chat at the virtual Oppenheimer 35th Annual Healthcare Life Sciences Conference on February 12, 2025 at 1:20 pm ET.